BCL2L1 and pancreatic neoplasm: We also found that pristimerin decreased the expression of NF-κB-regulated gene product Bcl-2, Bcl-XL and cyclin D1 in pancreatic cancer cells, thus suppressed the growth of pancreatic cancer cells.